Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

DeSimone RA, Costa VA, Kane K, Sepulveda JL, Ellsworth GB, Gulick RM, et al. Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. Transfusion. 2021;61(3):692-698.

Moon CS, Reglero C, Cortes JR, S Quinn A, Alvarez S, Zhao J, et al. induces NF-κB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98-113.

Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021;138(3):213-220.

Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021;118(22).

O'Brien DA, Kaye SM, Poppas PJ, Mahase SS, An A, Christos PJ, et al. Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis. J Neurosurg. 2021:1-11.

Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378-3389.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Kamboj M, McMillen T, Syed M, Chow HY, Jani K, Aslam A, et al. Evaluation of a Combined Multilocus Sequence Typing and Whole-Genome Sequencing Two-Step Algorithm for Routine Typing of . J Clin Microbiol. 2021;59(2).

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, et al. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021;5(1):44.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.